Literature DB >> 21639809

Been there, not done that--melanoma in the age of molecular therapy.

Marc S Ernstoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21639809     DOI: 10.1056/NEJMe1105792

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.

Authors:  Nuttapong Ngamphaiboon; Grace K Dy; Wen Wee Ma; Yujie Zhao; Thanyanan Reungwetwattana; Dawn DePaolo; Yi Ding; William Brady; Gerald Fetterly; Alex A Adjei
Journal:  Invest New Drugs       Date:  2014-11-05       Impact factor: 3.850

Review 2.  Adjunct primer for the use of national comprehensive cancer network guidelines for the surgical management of cutaneous malignant melanoma patients.

Authors:  Edibaldo Silva
Journal:  World J Surg Oncol       Date:  2012-04-06       Impact factor: 2.754

3.  Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.

Authors:  Brendon J Coventry; Martin L Ashdown
Journal:  Cancer Manag Res       Date:  2012-05-28       Impact factor: 3.989

4.  Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?

Authors:  Brendon J Coventry; Dominique Baume; Carrie Lilly
Journal:  Cancer Manag Res       Date:  2015-04-29       Impact factor: 3.989

5.  BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma.

Authors:  Priscilla Denise Zepeda-Lopez; Julio Cesar Salas-Alanis; Sonia Toussaint-Caire; Daniela Gutierrez-Mendoza; Elisa Vega-Memije; Saúl Lino Silva; Oscar Raul Fajardo-Ramírez; Gregorio Alcazar; María Guadalupe Moreno-Treviño; Hugo Alberto Barrera Saldaña
Journal:  Case Rep Oncol       Date:  2016-04-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.